Yona Geffen

Chief Tech/Sci/R&D Officer at GAMIDA CELL LTD.

Health Technology

Consumer Services

Profile

Yona Geffen is currently the Vice President-Research & Development at Gamida Cell Ltd.
Prior to this, she was the Chief Executive Officer at Avraham Pharmaceuticals Ltd.
from 2011 to 2016.
She also worked as a Director-Executive Drug Development at BioLineRx Ltd.
Dr. Geffen holds graduate and doctorate degrees from Ben-Gurion University of the Negev.

Yona Geffen active positions

Companies	Position	Start
GAMIDA CELL LTD.	Chief Tech/Sci/R&D Officer	2020-11-30

All active positions of Yona Geffen

Former positions of Yona Geffen

Companies	Position	End
Avraham Pharmaceuticals Ltd. Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel.	Chief Executive Officer	2016-11-30
BIOLINERX LTD.	Corporate Officer/Principal	-

See the detail of Yona Geffen's experience

Training of Yona Geffen

Ben-Gurion University of the Negev

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Yona Geffen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
BIOLINERX LTD.	Health Technology
GAMIDA CELL LTD.	Health Technology

Private companies	1
Avraham Pharmaceuticals Ltd. Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel.	Health Technology